We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed at $592.90 in the latest trading session, marking a +0.39% move from the prior day. This move lagged the S&P 500's daily gain of 1.9%. At the same time, the Dow added 2.05%, and the tech-heavy Nasdaq gained 1.75%.
REGN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $6.46, up 7.31% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.83 billion, down 5.6% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $27.70 per share and revenue of $7.77 billion. These results would represent year-over-year changes of +12.28% and -1.16%, respectively.
Any recent changes to analyst estimates for REGN should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.51% lower within the past month. REGN currently has a Zacks Rank of #3 (Hold).
In terms of valuation, REGN is currently trading at a Forward P/E ratio of 21.32. For comparison, its industry has an average Forward P/E of 28.1, which means REGN is trading at a discount to the group.
Investors should also note that REGN has a PEG ratio of 1.08 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.95 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 39, putting it in the top 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Gains But Lags Market: What You Should Know
Regeneron (REGN - Free Report) closed at $592.90 in the latest trading session, marking a +0.39% move from the prior day. This move lagged the S&P 500's daily gain of 1.9%. At the same time, the Dow added 2.05%, and the tech-heavy Nasdaq gained 1.75%.
REGN will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $6.46, up 7.31% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.83 billion, down 5.6% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $27.70 per share and revenue of $7.77 billion. These results would represent year-over-year changes of +12.28% and -1.16%, respectively.
Any recent changes to analyst estimates for REGN should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.51% lower within the past month. REGN currently has a Zacks Rank of #3 (Hold).
In terms of valuation, REGN is currently trading at a Forward P/E ratio of 21.32. For comparison, its industry has an average Forward P/E of 28.1, which means REGN is trading at a discount to the group.
Investors should also note that REGN has a PEG ratio of 1.08 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.95 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 39, putting it in the top 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.